though CFS is a distinct entity, features shared by both diseases suggest that CFS and fi bromyalgia represent the same underlying condition (9) . Additionally, because they are often accompanied by a noticeable mental health effect (9) , the presence of a potential neurotropic retroviral agent in both diseases could explain these similarities. Therefore, we studied the presence of XMRV and polytropic MLV-related retroviruses in a group of patients with fi bromyalgia.
During January 2010, blood samples were collected from 15 patients in whom fi bromyalgia had been previously diagnosed according to American College of Rheumatology criteria (www.rheumatology.org/ practice/clinical/classifi cation/fi bromyalgia/1990_Criteria_for_Classifi -cation_Fibro.pdf). Ten healthy blood donors served as controls. For XMRV screening, we used DNA extracted from 400 μL of whole blood collected in EDTA tubes by the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). Nested PCR was done by using 5 sets of primers corresponding to the gag (3) and env (2) regions of XMRV as described (2, 3, 7) . The fi rst round of PCR was conducted by using 500 ng of genomic DNA, equivalent to 7.5 × 10
4 nucleated blood cells, in a fi nal volume of 50 μL, by using the Expand High Fidelity PCR System (Roche Applied Science, Basel, Switzerland). A second round of PCR was conducted under the same conditions by using 5 μL of the fi rst reaction product. Details of the nested-PCR strategy were as follows: gag region was amplifi ed by outer primers 419F and 1154R (2) and 3 sets of inner primers: XMRV-FI-441/XMRV-RI-566 (3), MLV-GAG-I-F/MLV-GAG-I-R, and MLV-NP116/MLV-NP117 (7). Nested PCR for env was performed by using outer primers 5922F and 6273R (2) and 2 sets of inner primers: 5922F/6173R and 5942F/6159R (7). Primers for human β-globin were used as positive controls of human DNA amplifi cation (10) was used as a positive XMRV control. All samples were examined on a 2% agarose gel stained with ethidium bromide (Figure) . The overall sensitivity of the nested PCR procedure, estimated by spiking VP62 into negative samples, was 1-10 copies per sample.
Using highly sensitive PCR tools and a multiple set of primers to detect xenotropic and polytropic MLV-related sequences, we found no evidence of MLV-related sequences in blood cells from fi bromyalgia patients or controls. Our results agree with those from studies of CFS cohorts in Europe and North America that also failed to confi rm XMRV in blood samples (3) (4) (5) (6) . Technical issues or geographic specifi cities probably could not account for such a difference; therefore, these negative results raise concerns about the role of XMRV in these syndromes. Nevertheless, with this relatively small population we cannot absolutely exclude an association of XMRV or polytropic MLV-related viruses with fi bromyalgia. However, a proportion of fi bromyalgia cases with XMRV >22% would be unlikely (3/15 cases, 95% confi dence interval 0-3), which is clearly insuffi cient to support a signifi cant association between XMRV and fi bromyalgia.
Fibromyalgia does not appear to be associated with XMRV or polytropic MLV-related viruses. The role of these new agents in human disease, and specifi cally in CFS, remains to be clearly confi rmed in multicenter and standardized studies. 
